Aramchol meglumine
Phase 2Withdrawn 0 views this week 0 watching💤 Quiet
Interest: 17/100
17
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Sclerosing Cholangitis
Conditions
Primary Sclerosing Cholangitis
Trial Timeline
Jun 1, 2025 → Dec 1, 2027
NCT ID
NCT06095986About Aramchol meglumine
Aramchol meglumine is a phase 2 stage product being developed by Galmed Pharmaceuticals for Primary Sclerosing Cholangitis. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT06095986. Target conditions include Primary Sclerosing Cholangitis.
What happened to similar drugs?
20 of 20 similar drugs in Primary Sclerosing Cholangitis were approved
Approved (20) Terminated (6) Active (0)
Hype Score Breakdown
Clinical
12
Activity
0
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06095986 | Phase 2 | Withdrawn |
Competing Products
20 competing products in Primary Sclerosing Cholangitis